With a market capitalization (market cap) of $1.43B — a measure of how much the company is worth — Ascentage Pharma Group International ranks #2,280 among the 2,510 companies tracked, and 311th in Healthcare as of October 3, 2026. Shares trade at $15.37, down 3.36% on the day.
of 2,510 tracked
Market-cap change uses historical capitalization records. Share-price returns are a different series — they can diverge when the share count changes. Those returns are not a CAGR until you pick a start value, an ending value, and years. CAGR calculator. Market cap vs. stock price.
Year-end values and the chart both come from historical market-cap records, not from applying today's share count to past prices. Latest historical observation October 2, 2026. Ranking headline cap is the snapshot figure as of October 3, 2026.
| Year | As of | Market cap | Annual change | Year-end close |
|---|---|---|---|---|
| 2026 | Oct 2, 2026 | $1.43B | -41.00% | $15.37 |
| 2025 | Dec 31, 2025 | $2.43B | — | $26.24 |
Last observation of each calendar year from historical market-cap records. The current year is through the latest date, not a completed year-end. Share-price close is the matching session for context — we do not rebuild cap from today's share count.
Ranking figure $1.43B as of October 3, 2026.
Ascentage Pharma Group International's ranking market cap is the provider-reported capitalization on the same snapshot as the rest of this site, with a share price of $15.37 as of October 2, 2026. Charts and the year-end table use a separate historical market-cap series, last observed at $1.43B on October 2, 2026. See how the ranking works.
Live shares outstanding are not on the quote used for price, so this page does not invent a current share count. Shares outstanding vs. float.
The latest annual report (FY 2025) used a weighted-average 89,032,613 shares. That figure is an average for the year, not the live count in the market-cap formula.
This listing is an ADR. The market cap here is for the U.S. listing we rank; we do not have an ADR ratio, so we do not scale this figure to the parent company's local share count.
Book equity: assets minus liabilities on the latest annual report.
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Not in this snapshot
FY 2025 net worth
Largest U.S.-listed names in the same FMP sector — not a hand-picked competitor set.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #14 | Eli Lilly and Company LLY | $1.08T | -0.61% |
| #21 | Johnson & Johnson JNJ | $617.01B | -1.02% |
| #24 |
Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development. The company is dedicated to discovering and advancing therapeutic solutions for a range of medical conditions, including various cancers, chronic hepatitis B virus (HBV) infections, and age-related ailments. A cornerstone of its product pipeline is HQP1351, a BCR-ABL inhibitor specifically designed to address BCR-ABL1 mutants, notably those carrying the T315I mutation.
Summary from the company profile (Financial Modeling Prep). Principal financial figures above are for FY 2025.
Visit websiteAs of October 3, 2026, Ascentage Pharma Group International (AAPG) is worth $1.43B — that is its market capitalization, the total value of its outstanding shares on MarketCapLens.
A company’s net worth is its shareholders’ equity: assets minus liabilities on the balance sheet. That is book equity, not market cap. For FY 2025, Ascentage Pharma Group International’s book equity is about $1.34B. Market cap is the market value of the outstanding shares. As of October 3, 2026, its market cap is $1.43B. Book equity is an accounting remainder; market cap is a trading value. Neither is a person’s net worth.
Ascentage Pharma Group International ranks #2,280 among the 2,510 companies tracked on MarketCapLens. In Healthcare it ranks #311 of 350.
Fundamentals are annual. Figures labeled with their fiscal year. Live ratios use the current price against those annual earnings.
Too little price history
Not in this snapshot
FY 2025
| $464.35B |
| +1.11% |
| #36 | Merck & Co., Inc. MRK | $356.4B | +0.34% |
| #38 | UnitedHealth Group Incorporated UNH | $337.74B | +1.83% |
| #52 | Novartis AG NVS | $268B | -0.04% |
Companies immediately above and below in the overall ranking. They may be in a different sector.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #2277 | Pursuit Attractions and Hospitality, Inc. PRSU | $1.43B | +2.81% |
| #2278 | Stepan Co SCL | $1.43B | +2.39% |
| #2279 | REX American Resources Corporation REX | $1.43B | -0.87% |
| #2281 | Frontier Group Holdings, Inc. ULCC | $1.43B | +3.69% |
| #2282 | Savers Value Village, Inc. SVV | $1.42B | 0.00% |
| #2283 | Inhibrx Biosciences Inc. INBX | $1.42B | -0.96% |
Ascentage Pharma Group International’s ranking market cap of $1.43B comes from the same snapshot as the rest of this site, as of October 3, 2026. It is not share price multiplied by the FY 2025 weighted-average share count of 89,032,613. The historical market-cap series last observed $1.43B on October 2, 2026.
Over the past year, Ascentage Pharma Group International’s market cap is down 61.08%, using historical market-cap records rather than today’s share count applied to past prices.
Ascentage Pharma Group International (AAPG) shares trade at $15.37, down 3.36% on the day, as of October 3, 2026.
Live P/E is share price divided by annual earnings per share. It is blank when earnings are missing, zero, or negative — not a 0× multiple.